Grifols SA

Grifols SA’s steady stock rise, strong fundamentals, and evidence‑backed plasma‑derived therapies position it ahead of peers in Spain’s pharma market.

Short‑seller Kintbury ramps up Grifols stake, sparking debate on its future amid solid market backdrop.

Grifols shares dip below €10.88 amid market volatility, facing a patent cliff for Gamunex‑C, new biosimilar plans, and strategic M&A opportunities to protect revenue and boost investor confidence.

Grifols SA: In‑depth Ibex 35 analysis uncovers modest upside, regulatory costs, emerging‑market opportunities and hidden risks for investors.

Grifols SA stays a top Spanish investor focus, drawing significant trading activity amid AI‑driven market buzz, per a 350,000‑portfolio survey.

Grifols SA wins FDA approval for its plasma‑derived fibrinogen concentrate, boosting its specialty pharma line and positioning the company for steady revenue growth in a niche market.

FDA approves Grifols SA’s plasma‑derived fibrinogen for congenital deficiency, boosting rare‑disease therapy and investor confidence.

Grifols’ S&P rating upgrade and EMA approval for its Egyptian subsidiary signal a robust outlook, expanding its plasma‑derived market share while maintaining strong cash flow and debt management.

Grifols SA earns EMA certification for its Egypt plasma plant, becoming the first fully EU‑standard‑compliant facility in Africa/Middle East and boosting investor confidence.

Grifols SA stock swings on JPMorgan’s 7% target cut vs Qatar’s 2.5% stake hike—see why investors weigh short‑term caution against long‑term growth prospects.